Enrolling by invitationNCT06688838

Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

Studying Blau syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tongji Hospital
Intervention
Tofacitinib(drug)
Enrollment
24 enrolled
Eligibility
All sexes
Timeline
2017 – 2026

Study locations (1)

Collaborators

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Affiliated Hospital of Yunnan University · Pfizer · Wuhan Women and Children's Medical Center · Johns Hopkins Community Physicians

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06688838 on ClinicalTrials.gov

Other trials for Blau syndrome

Additional recruiting or active studies for the same condition.

See all trials for Blau syndrome →

← Back to all trials